Przejdź do zawartości
Merck

Notch signaling-related therapeutic strategies with novel drugs in neuroblastoma spheroids.

Journal of pediatric hematology/oncology (2012-11-07)
Sule Ayla, Ayhan Bilir, Burak C Soner, Ozlem Yilmaz-Dilsiz, Mine Ergüven, Gulperi Oktem
ABSTRAKT

Neuroblastoma is a severe pediatric tumor characterized by poor prognosis. Identification of novel molecular targets and diversion of investigations on new drug trials is mandatory for cancer therapy. In this study, vinorelbine tartrate, lithium chloride, clomipramine, and medroxyprogesterone acetate are used for the possible new treatment modalities in neuroblastoma cells. Notch and c-kit are novel molecules in cancer research, and Notch pathway is one of the emerging molecules in the neuroblastoma pathogenesis. Cytotoxic effects of these drugs at different time points, with different doses were studied in the SH-SY5Y human neuroblastoma cell line. Analysis of Notch and c-kit signaling with immunohistochemistry were constituted in multicellular tumor spheroids, and morphologic investigation was performed for digital imaging of cancer stem cells (CSCs) with electron microscopy. Size kinetics of spheroids was also determined after drug treatment. Results showed that all drugs were cytotoxic for neuroblastoma cells. Yet, this cytotoxic action did not correlate with the inhibitory effects in cell signaling. Neuroblastoma spheroids showed increased immunoreactivity of Notch signaling and c-kit. Altered ultrastructural CSCs morphology was observed after clomipramine and medroxyprogesterone acetate treatment compared with other drugs. Lithium chloride showed cellular membrane destruction for both CSCs and the remaining population. In this study, independent effects of cytotoxicity in tumor cells with respect to CSCs were determined. Redundant cells, which are the bulk population in tumor a compound, destroyed with therapy, were neither a target for treatment nor a remarkable investigation of cancer.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Sigma-Aldrich
Lithium chloride, ReagentPlus®, 99%
Sigma-Aldrich
Lithium chloride, ACS reagent, ≥99%
Sigma-Aldrich
Lithium chloride, Molecular Biology, ≥99%
Sigma-Aldrich
Medroxyprogesterone 17-acetate, ≥97% (HPLC)
Sigma-Aldrich
Lithium chloride, AnhydroBeads, −10 mesh, ≥99.9% trace metals basis
Sigma-Aldrich
Lithium chloride, powder, ≥99.98% trace metals basis
Sigma-Aldrich
Lithium chloride, AnhydroBeads, −10 mesh, 99.998% trace metals basis
Sigma-Aldrich
Lithium chloride, BioUltra, Molecular Biology, anhydrous, ≥99.0% (AT)
Supelco
Lithium chloride solution, 1 M in ethanol
Sigma-Aldrich
Lithium chloride, BioXtra, ≥99.0% (titration)
Sigma-Aldrich
Lithium chloride solution, 8 M, Molecular Biology, ≥99%
Medroxyprogesterone acetate, European Pharmacopoeia (EP) Reference Standard
Supelco
Clomipramine hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®
Supelco
Medroxyprogesterone 17-acetate, VETRANAL®, analytical standard
Sigma-Aldrich
Clomipramine hydrochloride, ≥98% (HPLC), powder
Sigma-Aldrich
Hematoxylin
Sigma-Aldrich
Hematoxylin, certified by the BSC
Medroxyprogesterone acetate for system suitability, European Pharmacopoeia (EP) Reference Standard